A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

BioWest Therapeutics Inc43 enrolled

Overview

The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatitis C, Chronic

Interventions

CelgosivirDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patient must be 18 to 65 years of age, inclusive. * Primary diagnosis of chronic HCV infection. Exclusion Criteria: * Patients who did not respond or relapsed following therapy with interferon.

Outcomes

Primary Outcomes

Safety analysis

Secondary Outcomes

Hepatitis C viral load

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.